Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?

Схожие документы

• Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
  по: Bersanelli, Melissa, et al.
  Опубликовано: (2017)
• The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the “inflamed tumor” to the “inflamed patient”
  по: Bersanelli, Melissa, et al.
  Опубликовано: (2021)
• The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a “transcriptomic compass”?
  по: Bersanelli, Melissa, et al.
  Опубликовано: (2019)
• Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study
  по: Buti, Sebastiano, et al.
  Опубликовано: (2017)
• Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy
  по: Buti, Sebastiano, et al.
  Опубликовано: (2016)